Cargando…
Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and efficacy of camrelizumab as neoadjuvant in lung cancer. Here, we present three patients who were diagnosed with IIIA squamou...
Autores principales: | Li, Xin, Xia, Chunqiu, Liu, Minghui, Liu, Jinghao, Dong, Ming, Zhao, Honglin, Xu, Song, Wang, Dan, Wei, Sen, Song, Zuoqing, Chen, Gang, Liu, Hongyu, Chen, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514096/ https://www.ncbi.nlm.nih.gov/pubmed/36176413 http://dx.doi.org/10.3389/fonc.2022.843116 |
Ejemplares similares
-
Survival Benefits for Pulmonary Adenocarcinoma With Malignant Pleural Effusion After Thoracoscopic Surgical Treatment: A Real-World Study
por: Li, Xin, et al.
Publicado: (2022) -
M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study
por: Wang, Shu, et al.
Publicado: (2023) -
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial
por: Chen, Jing, et al.
Publicado: (2023) -
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial
por: Lei, Jie, et al.
Publicado: (2023) -
Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)